In a statement, the company accused Hims of attempting to unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill, calling the move illegal mass compounding that poses a significant risk to patient safety. Novo pledged to take legal and regulatory action to protect patients, our intellectual property and the integrity of the US gold-standard drug approval framework. On a call with analysts that same day, Novo Nordisk CEO Mike Doustdar argued that consumers would be wasting $49 on the Hims product because, without Novos proprietary SNAC technology, the pill just simply doesnt work. Former FDA Commissioner Dr
Step 4: Depress the plunger slowly, allowing the water to run down the glass wall
Pentosidine can serve as a marker for detecting AD (86), with pregnant women consuming high-AGEs foods potentially exposing their fetus to a higher AGEs environment, thereby increasing the likelihood of AD development
, '
As the competitive landscape grows more complex, and litigation gets underway, dont miss the chance to benchmark your approach, manage risk, and engage in critical discussions with peers and policymakers at the forefront of the GLP-1 boom